Lipid-coated particles for treating viral infections
| DWPI Title: Antiviral carrier and compound for viral encephalitis infections, comprise porous core having pores, antiviral compound disposed in pore, and lipid layer disposed around core, where compound is 2-[piperazin-(2E)-ylideneamino]-benzamide |
| Abstract: The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein. |
| Use: The carrier and compound are used for treating viral infections such as viral encephalitis infections, and used for reducing brain viral load. The carrier and compound are used for treating a viral infection such as encephalitis infection, a viral infection, a bacterial infection, infections from a virus such as a mosquito-borne viral pathogen, an encephalitis virus (Venezuelan equine encephalitis virus, herpes virus (e.g., herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus), rabies virus, poliovirus, measles virus, an arbovirus (St. Louis encephalitis virus and West Nile encephalitis virus), bunyavirus (La Crosse strain and California encephalitis virus), arenavirus (lymphocytic choriomeningitis virus), reovirus (Colorado tick virus), henipavirus, flavivirus (Japanese encephalitis virus and St. Louis encephalitis virus), enterovirus, and Powassan virus, and infection from bacteria, fungi, and/or protozoa. The carrier is used for antiviral ML336 drug delivery.Test details are described but no results given. |
| Advantage: The carrier and compound improve delivery of such therapeutics to the desired site of action, utilize a lipid-coated particle to improve the solubility and/or stability of a drug (an antiviral drug), and utilize the lipid-coated particles to deliver compounds having reduced stability and/or solubility, while the liposome coating enables enhanced circulation time and biocompatibility. The utilized lipid-coated particle provides a reduction of brain viral load, as compared to administration of the antiviral compound alone. The compound has reduced stability and/or reduced solubility. |
| Novelty: Antiviral carrier and compound comprise: a porous core comprising pores; an antiviral compound disposed in at least one pore; and a lipid layer disposed around the porous core, where the antiviral compound has an aqueous solubility of 20-150 µg/ml in phosphate-buffered saline at a pH of 7.4 and/or a stability of 80% or less of a remaining amount of the compound after incubating in plasma for 3 hours, where the compound is 2-[piperazin-(2E)-ylideneamino]-benzamide (I), or its salt. |
| Filed: 6/17/2019 |
| Application Number: US16443316A |
| Tech ID: SD 14659.1 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |